Effect of Bortezomib on Total Cholesterol, Triglycerides and Histopathology Abdominal Aorta in Rats of Atherosclerosis Model
DOI:
https://doi.org/10.21776/ub.jkb.2020.031.02.5Keywords:
Atherosclerosis, bortezomib, cholesterol, proteasomes, triglyceridesAbstract
The effects of using proteasome inhibitors on atherosclerosis could be beneficial or detrimental. This study aimed to analyze the effects of proteasome inhibitors in the progression stage. Experimental animals (18 rats) were divided into three groups, namely control (C) as a group of rats given standard feed, P1 as atherosclerosis-induced rat group, and P2 as atherosclerosis-induced rat group and given proteasome inhibitors. Proteasome inhibitor administered was bortezomib at a dose of 50µg/kgBW/day intraperitoneally on day 1 and 3. After four days of treatment, the termination and measurement of serum total cholesterol, serum triglycerides, and abdominal aorta histopathology with hematoxylin-eosin staining were carried out. Serum total cholesterol levels were measured using the CHOD-PAP (Cholesterol Oxidase-Peroxidase Aminoantypirin) method, whereas serum triglyceride levels were measured using the GPO-PAP (glycerol phosphatase oxidase−phenol4-amino antipyrene peroxidase) method. Histopathological assessment was carried out with a scoring system in 9 fields of view with a 400x magnification, which was then averaged. The ANOVA test showed significant differences in serum total cholesterol, serum triglycerides, and abdominal aortic histopathology between atherosclerosis and control groups, but there were no significant differences in the administration of bortezomib in atherosclerosis except in serum triglyceride levels. It can be concluded that the administration of 50µg/kg bortezomib for four days in the rats model of the progression stage of atherosclerosis can decrease serum triglyceride levels, although it can not inhibit the formation of atherosclerotic lesions and has no effect on serum total cholesterol.Â
Downloads
References
Barquera S, Pedroza-TobÃas A, Medina C, et al. Global Overview Of The Epidemiology Of Atherosclerotic Cardiovascular Disease. Archives of Medical Research. 2015;46(5):328–38.
Badan Penelitian Dan Pengembangan Kesehatan Kementerian Kesehatan RI. Riset Kesehatan Dasar 2013. Kementrian Kesehatan Republik Indonesia. 2013.
Da̧bek J, Kułach A, dan Ga̧sior Z. Nuclear Factor Kappa-Light-Chain-Enhancer Of Activated B Cells (NF-ΚB): A New Potential Therapeutic Target In Atherosclerosis? Pharmacological Reports. 2010;62(5):778–83.
Wu JT, dan Wu LL. Association Of Soluble Markers With Various Stages And Major Events Of Atherosclerosis. Annals of Clinical & Laboratory Science. 2005;35(3):240–50.
Mizuno Y, Jacob RF, dan Mason RP. Inflammation And The Development Of Atherosclerosis. Journal of atherosclerosis and thrombosis. 2011;18(5):351–8.
Herrmann J, Lerman LO, dan Lerman A. On To The Road To Degradation: Atherosclerosis And The Proteasome. Cardiovascular Research. 2010;85(2):291–302.
Ismawati, Oenzil F, Yanwirasti, dan Yerizel E. Changes In Expression Of Proteasome In Rats At Different Stages Of Atherosclerosis. Anatomy & Cell Biology [Internet]. 2016;49(2):99. Accessed on: https://synapse.koreamed.org/DOIx.php?id=10.5115/acb.2016.49.2.99
Eldridge AG, dan O’Brien T. Therapeutic Strategies Within The Ubiquitin Proteasome System. Cell Death and Differentiation. 2010;17(1):4–13.
Ludwig A, Fechner M, Wilck N, et al. Potent Anti-Inflammatory Effects Of Low-Dose Proteasome Inhibition In The Vascular System. Journal of Molecular Medicine. 2009;87(8):793–802.
Wilck N, Fechner M, Dreger H, et al. Attenuation Of Early Atherogenesis In Low-Density Lipoprotein Receptor-Deficient Mice By Proteasome Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32(6):1418–26.
Wilck N, Fechner M, Dan C, Stangl V, Stangl K, dan Ludwig A. The Effect Of Low-Dose Proteasome Inhibition On Pre-Existing Atherosclerosis In LDL Receptor-Deficient Mice. International Journal of Molecular Sciences. 2017;18(4).
Ismawati, Oenzil F, Yanwirasti, dan Yerizel E. Analisis Konsentrasi Low Density Lipoprotein Teroksidasi Serum Pada Tahapan Aterosklerosis. Jurnal Kedokteran Brawijaya. 2017;29(2017).
Oliva J, French SW, Li J, dan Bardag-Gorce F. Proteasome Inhibitor Treatment Reduced Fatty Acid, Triacylglycerol And Cholesterol Synthesis. Experimental and molecular pathology. 2012;93(1):26–34.
Reddy HK, Laxmikanth B, Sujatha P, dan Modi P. A Study Of Hs-CRP And Lipid Profile In Overweight Individuals. International Journal of Medical Science and Public Health. 2013;2(2):399–403.
Wilck N, dan Ludwig A. Targeting The Ubiquitin-Proteasome System In Atherosclerosis: Status Quo, Challenges, And Perspectives. Antioxidants and Redox Signaling. 2014;(0):1-20
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
